Bioline RX Ltd Sponsored ADR (BLRX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioLineRx Ltd. has announced substantial commercial achievements for APHEXDA, including securing payer coverage for roughly 95% of U.S. lives and initiating a Phase 2b trial for pancreatic cancer treatment. The company has also reported a successful launch of APHEXDA in the U.S. and positive progress in collaborations, with financial results showing $4.8 million in revenue for the year 2023.
For further insights into BLRX stock, check out TipRanks’ Stock Analysis page.